Suppr超能文献

长期服用单硝酸异山梨酯不会损害肝硬化患者的肾功能。

Long-term administration of isosorbide-5-mononitrate does not impair renal function in cirrhotic patients.

作者信息

Salerno F, Borroni G, Lorenzano E, Solenghi D, Cazzaniga M, Bissoli F, Ceriani R, deFranchis R

机构信息

Istituto di Medicina Interna, Università degli Studi di Milano, Italy.

出版信息

Hepatology. 1996 May;23(5):1135-40. doi: 10.1053/jhep.1996.v23.pm0008621145.

Abstract

Isosorbide-5-mononitrate (Is-5-Mn), alone or combined with beta-blockers, has been proposed for prophylaxis of variceal bleeding in cirrhosis. However, renal insufficiency, might be an important undesirable effect of this therapy, especially in patients with ascites. We assessed the changes in renal function induced in 26 cirrhotic patients by acute or chronic administration of Is-5-Mn. The acute administration of 20 mg of Is-5-Mn to 21 patients reduced mean blood pressure (83.4 +/- 2.4 vs. 92.8 +/- 3.4 mm Hg, P < .001), urine volume (5.5 +/- 0.8 vs. 8.7 +/- 1.1 mL/min, P < .05), urine sodium excretion (114 +/- 19 vs. 244 +/- 41 muEq/min, p < .001), urine potassium excretion (41 +/- 3.4 vs. 67 +/- 8.5 muEq/min, P < .001), and atrial natriuretic factor (74 +/- 10 vs. 98 +/- 12 pg/mL, P < .005). The glomerular filtration rate was decreased in the 11 patients with ascites (57 +/- 9 vs. 68 +/- 12 mL/min, P < .05), and plasma renin activity was increased in 4 ascitics. Twenty-one patients (16 from the acute study + 5 other patients) were given Is-5-Mn for 3 months at the dose of 80 mg/d. This did not affect blood pressure and renal function in patients without ascites, but reduced mean blood pressure (91.9 +/- 3.4 vs. 89.6 +/- 3 mm Hg, P < .05), urine volume (5.8 +/- 1.1 vs. 3.4 +/- 0.9 mL/min, P < .05), and urine sodium excretion (205 +/- 38 vs. 99 +/- 16 muEq/min, P < .01) in those with ascites. There were no changes in glomerular filtration rate and renal plasma flow, while plasma renin activity increased in only 3 patients with ascites and 1 without. Systemic hemodynamics and renal function of cirrhotic patients, especially those with ascites, are affected adversely by acute administration of Is-5-Mn. Long-term administration of the drug is well tolerated by compensated patients and does not affect renal plasma flow nor glomerular filtration rate, but can induce hypotension and sodium retention in patients with ascites.

摘要

5-单硝酸异山梨酯(Is-5-Mn)单独使用或与β受体阻滞剂联合使用,已被提议用于预防肝硬化患者的静脉曲张出血。然而,肾功能不全可能是这种治疗的一个重要不良影响,尤其是在腹水患者中。我们评估了26例肝硬化患者急性或慢性给予Is-5-Mn后肾功能的变化。对21例患者急性给予20 mg Is-5-Mn后,平均血压降低(83.4±2.4 vs. 92.8±3.4 mmHg,P<.001),尿量减少(5.5±0.8 vs. 8.7±1.1 mL/min,P<.05),尿钠排泄减少(114±19 vs. 244±41 μEq/min,P<.001),尿钾排泄减少(41±3.4 vs. 67±8.5 μEq/min,P<.001),心房利钠因子降低(74±10 vs. 98±12 pg/mL,P<.005)。11例腹水患者的肾小球滤过率降低(57±9 vs. 68±12 mL/min,P<.05),4例腹水患者的血浆肾素活性升高。21例患者(16例来自急性研究+5例其他患者)以80 mg/d的剂量给予Is-5-Mn 3个月。这对无腹水患者的血压和肾功能没有影响,但降低了有腹水患者的平均血压(91.9±3.4 vs. 89.6±3 mmHg,P<.05)、尿量(5.8±1.1 vs. 3.4±0.9 mL/min,P<.05)和尿钠排泄(205±38 vs. 99±16 μEq/min,P<.01)。肾小球滤过率和肾血浆流量没有变化,而仅3例腹水患者和1例无腹水患者的血浆肾素活性升高。肝硬化患者,尤其是腹水患者,急性给予Is-5-Mn会对全身血流动力学和肾功能产生不利影响。代偿期患者对该药物的长期给药耐受性良好,且不影响肾血浆流量和肾小球滤过率,但可导致腹水患者低血压和钠潴留。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验